Pilot Randomized Trial Demonstrates that PCI of Non-Flow-Limiting Vulnerable Plaques May be Safe with Favorable Long-Term Clinical Outcomes – Newswise

Newswise NEW YORK October 14, 2020 New data from PROSPECT ABSORB, a pilot randomized trial of percutaneous coronary intervention (PCI) of non-flow-limiting vulnerable plaques in native coronary arteries, found that PCI was safe, substantially enlarged follow-up lumen areas, and was associated with favorable long-term clinical outcomes.

Findings were reported today at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the worlds premier educational meeting specializing in interventional cardiovascular medicine. The study was also published simultaneously in the Journal of the American College of Cardiology.

Acute coronary syndromes (ACS) commonly arise from plaque rupture and thrombosis of coronary artery lesions that angiographically appear mild but pathologically contain large plaque burden (PB) with an organized lipid-rich necrotic core that is separated from the lumen by a thin fibrous cap. Known as vulnerable plaques, these thin-cap fibroatheromas place patients at risk for future adverse events, including acute myocardial infarction (MI) and cardiac death. Vulnerable plaques may be identified by several noninvasive and invasive imaging techniques.

PROSPECT ABSORB was an investigator-sponsored, multicenter, single-blinded, active-treatment-controlled randomized trial that was embedded into the PROSPECT II natural history study. Between June 10, 2014 and December 20, 2017, 902 patients at 16 sites were enrolled in PROSPECT II.

Three-vessel imaging was performed with a combination intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS) catheter after successful PCI of all flow-limiting coronary lesions in 898 patients presenting with MI. Among these, 182 patients at 15 centers with an angiographically non-obstructive stenosis not intended for PCI but with IVUS plaque burden 65% were randomized to treatment of the lesion with a bioresorbable vascular scaffold (BVS) plus guideline-directed medical therapy (GDMT) (n=93) vs. GDMT alone (n=89).

The primary effectiveness endpoint was the IVUS-derived minimum lumen area (MLA) at protocol-driven 25-month follow-up. The primary (non-powered) safety endpoint was target lesion failure (TLF; composite of cardiac death, target vessel-related MI or clinically driven target lesion revascularization) at 24 months. Angiographic follow-up at 25 months was completed in 167 patients (91.8%), and median clinical follow-up was 4.1 years.

The follow-up MLA in BVS-treated lesions was 6.92.6 mm2 compared with 3.01.0 mm2 in GDMT alone-treated lesions (least square means difference 3.9 mm2, 95% CI 3.3-4.5, P<0.0001). TLF at 24 months occurred in similar rates of BVS-treated and GDMT alone-treated patients (4.3% vs. 4.5%; P=0.96). The secondary (non-powered) clinical effectiveness endpoint of randomized lesion-related MACE to the time of latest follow-up occurred in 4.3% BVS-treated patients vs. 10.7% GDMT alone-treated patients (OR 0.38, 95% CI 0.11-1.28, P=0.12).

The results from PROSPECT ABSORB indicate that PCI of vulnerable plaques may safely enlarge the lumen and change the structure of the lesion, theoretically reducing its propensity for thrombosis and progression, said Gregg W. Stone, MD. Dr. Stone is Director of Academic Affairs, Mount Sinai Heart Health System and Professor of Medicine at The Zena and Michael A. Wiener Cardiovascular Institute of the Icahn School of Medicine at Mount Sinai. Dr. Stone and Dr. David Erlinge served as study co-chairs.

The favorable randomized lesion-related MACE rates observed after BVS treatment compared with medical therapy alone warrants the performance of an adequately powered randomized trial to determine whether PCI treatment of vulnerable plaques improves patient outcomes.

The PROSPECT ABSORB trial was sponsored by the Uppsala Clinical Research Center, Uppsala University Hospital, Uppsala, Sweden. The trial was funded by research grants from Abbott Vascular, Infraredx and The Medicines Company. Dr. Stone reported the following disclosures: speaker honoraria from Cook; Consultant to Valfix, TherOx, Robocath, HeartFlow, Gore, Ablative Solutions, Miracor, Neovasc, Abiomed, Ancora, Vectorious, and Cardiomech; Equity/options from Ancora, Qool Therapeutics, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, and Valfix.

About CRF

The Cardiovascular Research Foundation (CRF) is one of the worlds leading nonprofit organizations specializing in interventional cardiology innovation, research, and education. CRF is dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For nearly 30 years, CRF has helped pioneer medical advances and educated doctors on the latest treatments for heart disease. CRF is comprised of the CRF Skirball Center for Innovation, CRF Clinical Trials Center, CRF Center for Education, CRF Digital, TCTMD, and Structural Heart: The Journal of the Heart Team.

Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of CRF and the premier educational meeting specializing in interventional cardiovascular medicine. Now in its 32nd year, TCT features major medical research breakthroughs and gathers leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field.

For more information, visit http://www.crf.org and http://www.tctconference.com.

###

View post:
Pilot Randomized Trial Demonstrates that PCI of Non-Flow-Limiting Vulnerable Plaques May be Safe with Favorable Long-Term Clinical Outcomes - Newswise